sars-cov-2 vlp vaccine-alpha (british) variant - Turkey
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 26, 2021 (NCT04962893)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04962893 | Phase 2 | Jun 26, 2021 | Bilkent University, MonitorCRO, Nobel Pharmaceuticals, The Scientific and Technological Research Council of Turkey |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bilkent University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| MonitorCRO | For profit | 1 | 0 | 1 | 2021 |
| Nobel Pharmaceuticals | For profit | 1 | 0 | 1 | 2021 |
| The Scientific and Technological Research Council of Turkey | Government | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1